Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on ...

Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...

Pfizer's Phase 3 trial showed sasanlimab with BCG improved event-free survival in high-risk NMIBC patients. Sasanlimab's safety profile aligns with known PD-1 inhibitors and BCG data from previous ...

(Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence ...